Entity

Time filter

Source Type


Chomet M.,Radiopharmacie et service de medecine nucleaire de lhOpital Tenon | Cross T.,Radiopharmacie et service de medecine nucleaire de lhOpital Tenon | Geraudie B.,Radiopharmacie et service de medecine nucleaire de lhOpital Tenon | Chipan A.-S.,Radiopharmacie et service de medecine nucleaire de lhOpital Tenon | And 2 more authors.
Medecine Nucleaire | Year: 2014

Gallium-68 is a radionuclide, which has, because of its favorable physical characteristics similar to those of fluorine-18, gained a great interest for labeling PET tracers. Furthermore, it is available onsite at the radiopharmacy, by elution of a 68Ge/68Ga generator that has a shelf life of around one year, which approximates the versatility of 99mTc in the labeling of tracers for scintigraphy. After a brief historical overview, this article lists the necessary equipment and components, and the choices to be made (currently and in the near future) to implement, in a radiopharmacy, 68Ga-labelling of PET tracers for a nuclear medicine department. © 2014 Elsevier Masson SAS. Source


Montravers F.,University Pierre and Marie Curie | Nataf V.,Radiopharmacie et service de medecine nucleaire de lhOpital Tenon | Bartovic M.,Comenius University | Cich D.,Comenius University | And 7 more authors.
Medecine Nucleaire | Year: 2014

This article focuses on the indication and the choice of tracer for PET/CT in case of neuroendocrine tumours (NET) of the small intestine, which are the most common digestive NETs. PET/CT can be used to search for the primary NET in case of detection of a metastasis, for staging and determination of resectability, for restaging, for optimising and determining the efficacy of therapeutic modalities in extended or recurrent forms. Currently, three types of PET tracers are routinely used: FDG can be useful in the case of aggressive NET especially the duodenum and proximal jejunum, FDOPA is the best tracer in the case of NET of distal jejunum or of ileum, the labeled somatostatin analogues 68Ga in the case of well-differentiated NET from the duodenum or proximal jejunum, or irrespective of the location of primary NET if treatment with somatostatin analogue is intended, to confirm the overexpression of somatostatin receptors by lesions. © 2014 Elsevier Masson SAS. Source

Discover hidden collaborations